Impact of Metabolic Syndrome and Diabetes on Prognosis and Outcomes With Early Percutaneous Coronary Intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) Trial

Authors:

Abstract
No abstract available
Funding Information
  • Merck
  • Pfizer
  • Bristol-Myers Squibb
  • Fujisawa
  • Kos Pharmaceuticals
  • Datascope
  • AstraZeneca
  • Key Pharmaceutical
  • Sanofi-Aventis
  • First Horizon
  • GE Healthcare
  • Amgen
  • Bristol-Myers Squibb
  • Sanofi-Aventis
  • Eli Lilly
  • Johnson & Johnson
  • Evaheart Medical
  • Merck

This publication has 28 references indexed in Scilit: